In the past 15 years, the incidence of hospital infections caused by yeasts of the genus Candida has shown a steady increase (1, 31, 34) . Since the clinical symptoms of deep candidosis are nonspecific (4), the mycological laboratory can play an essential role by providing assistance to the clinician with the establishment of a diagnosis. Furthermore, this biological diagnosis must be made early, since timely initiation of antifungal therapy is essential for a favorable prognosis (1, 31) . To reach these goals, three types of biological procedures are available, namely, mycological examination and tests for detection of antibodies and antigen; each of these has its limitations. The subject has been extensively discussed in the literature (2, 9, 15, 27) . It is generally agreed that these three types of tests may complement each other and that mycological and serological surveys of high-risk patients, defined according to clinical data, are necessary. The aim of this study was to evaluate the diagnostic value of two commercially available latex agglutination tests, i.e., Cand-Tec (Ramco Laboratories, Inc., Houston, Tex.) which has been available for several years (7, 11, 12) , and Pastorex Candida (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France), which was introduced more recently (13, 23) . This evaluation was made in the context of a routine mycological laboratory to which mycological and serological samples are sent at the initiative of clinicians. It involved 19 patients who were retrospectively selected on the basis of mycological and clinical evidence of deep C. albicans infection and the availability of several * Corresponding author. serial serum samples taken near the date of a positive culture of samples from normally sterile sites. Our routine serological procedure involves the detection of antibodies by cocounterimmunoelectrophoresis (Co-CIE) and an indirect immunofluorescence assay (IFA) (29) plus antigen detection by the Cand-Tec test in cases of nonsignificant antibody levels (12) . The objective of the present analysis was therefore to assess the advantages, if any, of Pastorex Candida compared with those of Cand-Tec.
MATERLILS AND METHODS
Human sera. (i) Sera from patients with C. albicans infection. The following criteria were applied to laboratory and clinical files as retrospective selection rules: (i) selection of patients having presented evidence of the presence of C. albicans, which was isolated at least once in large quantities from normally sterile sites (blood, catheter, drain, wound, peritoneal cavity, gastric or lung biopsy specimens, bile, pancreatic cyst, pericardial fluid); (ii) availability of serial serum samples for the corresponding patients taken near the date of positive cultures; and (iii) subsequent analysis of the selected patients' clinical files (together with the physicians in charge of the patients), leading to consideration of candidosis as highly probable once it was integrated into the underlying conditions (e.g., fever resistant to antibacterial agents and response to antifungal therapy). Application of this procedure for the period between February 1988 and May 1989 led to the selection of 73 serum samples from 18 patients from the surgery, intensive care, and hematology wards of the Lille University Hospital.
Details concerning patients with C. albicans infection are given in Tables 1 and 2. In Tables 1 and 2, the data are for 19 patients, not 18 patients, since 1 patient who underwent two episodes of invasive candidosis in a 1-year interval (separated by a total recovery) was treated as two different patients (patients A9 and B5).
(ii) Control sera. Four groups of control individuals (a total of 60 individuals) were tested in order to determine the specificity of the methods. The first group consisted of 10 members of the laboratory staff, the second group included 20 surgery patients without any sign of clinical candidosis, the third group encompassed 10 patients with immunologically confirmed aspergillosis and 2 patients with allergic bronchopulmonary aspergillosis (3), and the fourth group included 18 patients in acute phases of parasitic diseases, as follows: 13 patients with malaria and 1 patient each with fascioliasis, schistosomiasis, filariasis, echinococciasis, and amebiasis.
Mycological examinations. Cultures were grown on Sabouraud glucose agar containing kanamycin (800 ,g/ml). The isolates were identified as C. albicans on the basis of germ tube (20) and chlamydosporulation (32) tests.
Antibody detection. Two methods for antibody detection were used.
(i) Co-CIE. Co-CIE (bio Merieux, Marcy l'Etoile, France) has been described in detail before (29 Relying on the results obtained with Co-CIE and IFA, the following conclusions were assigned to the serum samples: N, no immunological suspicion of candidosis (no CSPL and IFA < 400); S, immunologically suspected candidosis (presence of CSPL and/or IFA > 400); C, immunologically confirmed candidosis (strong CSPL and IFA > 400).
Detection of circulating antigens. Both antigen detection kits were used according to the manufacturer's instructions.
The Cand-Tec test (Ramco) uses latex beads coated with a polyclonal rabbit anti-Candida serum against an unknown antigen (12). The test is positive when serum, which is diluted 1/4, agglutinates the latex beads. Serial dilutions of serum were tested to determine the antigen titer, which is defined as the reciprocal of the highest serum dilution that still causes agglutination.
In the Pastorex Candida test (Sanofi Diagnostics Pasteur), the latex beads were sensitized with a monoclonal antimannan antibody (23) . Serum samples were incubated with a serum treatment solution at 100°C. After centrifugation, the supematants were incubated with the latex beads. A serum sample scored positive when undiluted supernatant agglutinated the latex beads. Serial dilutions of the supernatant were tested so that we could obtain semiquantitative results.
RESULTS
The patients were divided into two groups according to their antibody responses as analyzed by Co-CIE and IFA. Group A consisted of 12 patients with immunologically confirmed candidosis, as established by these routine procedures. The average number of serum samples per patient in this group was 2.8 + 1.3 (Table 1 ). Group B included seven patients who failed to produce an antibody response, which was considered indicative of infection, but they were judged to suffer from an invasive candidosis on clinical and mycological grounds. The average number of serum samples per patient in this group was 5.7 ± 3.1 ( Table 2) .
For group A patients (Table 1) , Cand-Tec was positive at a significant titer for 5 of 12 patients, whereas Pastorex Candida was positive for 3 patients. For group B patients (Table 2) , four of seven patients were positive by Cand-Tec; Pastorex Candida yielded positive results for all seven patients. When the results for both patient groups were combined, 9 of 19 cases scored positive by Cand-Tec, as opposed to 10 of 19 by Pastorex Candida.
Patients were often positive by only one test (Tables 1 and  2 ). Five patients (patients A6, All, B3, B4, and B6) were negative by Cand-Tec but positive by Pastorex Candida, while four patients (patients A3, A4, A9, and A12) remained negative by Pastorex Candida but were positive by CandTec. Both tests failed to detect antigen in five patients (patients Al, A2, A5, A8, and A10). A remarkable feature shared by both tests in both groups of patients was that when more than one serum sample was available per patient, antigenemia was always transient. For the serum samples tested and sent at the initiative of clinicians, the minimum delay observed for the appearance of detectable antigen by Cand-Tec and Pastorex were, respectively, 4 days (patient B7) and 1 day (patient A6); conversely, it was possible to observe the disappearance of detectable antigens in both tests within 48 h (patient B5, Cand-Tec; patient B7, Pastorex). The longest antigenemia period detected without any intervening negative test was of 47 days and concerned the Pastorex Candida in patient B5. Figure 1 shows the sensitivities of both tests as a function of the number of serum samples tested per patient. The sensitivity of the Pastorex Candida increased when there were increasing numbers of serum samples available for each patient. In the entire patient population, the sensitivity of Pastorex was 52.6%. When data for the patients who provided only one or two samples were omitted, the sensitivity increased to 76.9%, eventually attaining 100% in patients who provided five or more serum samples. The Cand-Tec test did not show such a correlation.
Both tests were negative for samples from the healthy controls and from surgery patients ( samples provided by the Pastorex-positive patients. When patients who provided only one or two serum samples were omitted from the analysis, the sensitivity of Pastorex rose to 76.9%. This correlation between sensitivity and number of serum samples could not be observed with Cand-Tec, but it has been described by Burnie and Williams (7). In their study, the average number of samples per patient was 3.1 for Cand-Tec-negative patients and 9.7 for Cand-Tec-positive ones. In the same context, the time interval between samples is important. It is noteworthy that the average interval between the time that serum samples were obtained from four of five patients who were negative by both tests was 10 days or more.
We observed discordant results between the two tests in nine patients: five patients were negative by Cand-Tec and positive by Pastorex, while four patients were negative by Pastorex and positive by Cand-Tec. Only 12.5% of the serum samples were positive when they were tested by using both tests. This observation can be explained by the fact that the two latex agglutination tests detect different antigens. The rat monoclonal antibody EB-CA1, which is used in the Pastorex test, recognizes mannan, a major cell wall polysaccharide, from C. albicans, C. tropicalis, C. glabrata, C. guilliermondii, and to a lesser extent, C. pseudotropicalis and C. parapsilosis (14) . The antigen detected by Cand-Tec, however, has not been identified, but it is certainly different from mannan (12, 30) . The high degree of discord between the two tests suggests that the detection of more than one antigen may improve the sensitivity.
The prognosis of the patient improves when a diagnosis can be established in an early phase of the infection (31) . It is therefore important to see whether the antigen tests would have allowed an earlier diagnosis. In the nine positive patients, the Cand-Tec test turned positive in five patients before cultures became positive or antibody levels considered as significative of candidosis were detected (29) . In the 10 Pastorex-positive patients, Pastorex Candida was the first indication of invasive disease in six of them. Both latex In this study, both tests were very specific; all 60 control samples were negative by Pastorex Candida (100% specificity), and only 1 control sample was positive by Cand-Tec (98.3% specificity) ( Table 3 ). This positive sample, which was from a patient with aspergillosis, may have been a true-positive result, since serological results were consistent with immunologically confirmed candidosis. For Pastorex Candida, the high specificity is in agreement with earlier findings (23) . The specificity of Cand-Tec reported in other studies varied considerably (6, 8, 12, 16, 25, 26, 28) .
Results of our study suggest that the laboratory diagnosis of invasive candidosis benefits from an integrated, kinetic approach in which patients suspected of having candidosis or, preferably, patients at risk of candidosis are submitted to mycological surveillance, serological tests, and antigen detection at regular time intervals. This approach allows physicians to follow kinetics of antibody fluctuations (29) 
